Zacks Investment Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
Other funds holding EBS
PCM
Zacks Investment Management's EBS Position: Q1 2026 in Review
Zacks Investment Management sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 11,432 shares — an estimated $141K sold.
Zacks Investment Management first reported a position in EBS in Q1 2014 and held it in 16 quarters. The position peaked at $4.12M in Q4 2015. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- Zacks Investment Management reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
- Zacks Investment Management sold 11,432 Emergent Biosolutions shares in Q1 2026, an estimated $141K.
- Zacks Investment Management first reported a position in Emergent Biosolutions in Q1 2014 and held it in 16 quarters.
- Zacks Investment Management's Emergent Biosolutions position peaked at $4.12M in Q4 2015.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.